AVALO THERAPEUTICS, INC. (AVTX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2025-12-31..
Gross margin
Overview →Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 59.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2025-12-31 | (m) | $59.00K | (m) | (m) |
| 2025-09-30 | (m) | $192.00K | (m) | (m) |
| 2024-12-31 | (m) | $441.00K | (m) | (m) |
| 2024-09-30 | (m) | $820.00K | $-674.00K | (m) |
| 2024-06-30 | (m) | $807.00K | $288.00K | (m) |
| 2024-03-31 | (m) | $1.45M | $653.00K | (m) |
| 2023-12-31 | (m) | $1.92M | $1.28M | (m) |
| 2023-09-30 | (m) | $2.25M | $2.13M | (m) |
| 2023-06-30 | (m) | $16.96M | $2.41M | (m) |
| 2023-03-31 | (m) | $17.35M | $3.27M | (m) |
| 2022-12-31 | (m) | $18.05M | $3.43M | (m) |
| 2022-09-30 | (m) | $17.37M | $3.24M | (m) |
| 2022-06-30 | (m) | $3.77M | $3.62M | (m) |
| 2022-03-31 | (m) | $6.10M | $2.13M | (m) |
| 2021-12-31 | (m) | $5.40M | $1.49M | (m) |
| 2021-09-30 | (m) | $6.68M | $1.15M | (m) |
| 2021-06-30 | (m) | $6.44M | $315.20K | (m) |
| 2021-03-31 | (m) | $4.42M | $311.20K | (m) |
| 2020-12-31 | (m) | $6.70M | $300.20K | (m) |
| 2020-09-30 | (m) | $5.78M | $-3.59M | (m) |
| 2020-06-30 | (m) | $6.87M | $321.74K | (m) |
| 2020-03-31 | (m) | $6.93M | $-1.25M | (m) |
| 2019-12-31 | (m) | $6.75M | $-566.52K | (m) |
| 2019-09-30 | (m) | $20.46M | $5.32M | (m) |
| 2019-06-30 | (m) | $18.92M | $7.00M | (m) |
| 2019-03-31 | (m) | $19.26M | $8.56M | (m) |
| 2018-12-31 | (m) | $18.33M | $7.48M | (m) |
| 2018-09-30 | (m) | $15.58M | (m) | (m) |
| 2018-06-30 | (m) | $36.54M | (m) | (m) |
| 2018-03-31 | (m) | $27.82M | (m) | (m) |
| 2017-12-31 | (m) | $27.81M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $1.15M | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |